No Data
No Data
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
Extrawell Pharmaceutical Holdings' (HKG:858) Earnings Might Be Weaker Than You Think
EXTRAWELL PHAR: Interim Report 2024/25
Express News | Extrawell Pharmaceutical Holdings H1 Revenue HKD 30.8 Million
EXTRAWELL PHAR: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
Extrawell Pharmaceutical to Turn to Profit in Fiscal H1